Holen Sie sich die Stockscreener-App
23.13
0.43%
-0.10
Handel nachbörslich:
23.13
Schlusskurs vom Vortag:
$23.23
Offen:
$23.22
24-Stunden-Volumen:
4.06M
Relative Volume:
0.81
Marktkapitalisierung:
$11.55B
Einnahmen:
$4.72B
Nettoeinkommen (Verlust:
$-232.00M
KGV:
-49.60
EPS:
-0.4663
Netto-Cashflow:
$284.00M
1W Leistung:
-1.41%
1M Leistung:
-1.15%
6M Leistung:
+12.72%
1J Leistung:
+185.56%
1-Tages-Spanne:
$22.87
$23.41
1-Wochen-Bereich:
$22.83
$24.43
52-Wochen-Spanne:
$8.02
$27.72
Elanco Animal Health Inc Stock (ELAN) Company Profile
Firmenname
Elanco Animal Health Inc
Sektor
Telefon
877-352-6261
Adresse
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
23.13 | 11.60B | 4.72B | -232.00M | 284.00M | -0.4663 |
TAK
Takeda Pharmaceutical Co Adr
|
17.78 | 56.39B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
119.04 | 50.78B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.59 | 43.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.26 | 36.81B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
580.51 | 25.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-11-21 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2025-11-19 | Hochstufung | Argus | Hold → Buy |
| 2025-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-07-17 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-06-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-12-09 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-09-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | Hochstufung | Stifel | Hold → Buy |
| 2023-12-19 | Eingeleitet | Jefferies | Buy |
| 2023-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-04-20 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-21 | Herabstufung | Goldman | Buy → Sell |
| 2022-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-28 | Herabstufung | Stifel | Buy → Hold |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-06-15 | Hochstufung | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-05-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2021-04-15 | Eingeleitet | Stifel | Buy |
| 2021-03-22 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2021-02-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | Herabstufung | Argus | Buy → Hold |
| 2020-11-09 | Herabstufung | Barclays | Overweight → Underweight |
| 2020-08-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-08-04 | Fortgesetzt | Goldman | Buy |
| 2020-07-27 | Herabstufung | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-19 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | Eingeleitet | Barclays | Overweight |
| 2019-08-26 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Neutral |
| 2019-03-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-02-12 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-23 | Eingeleitet | UBS | Sell |
| 2019-01-15 | Eingeleitet | Argus | Buy |
| 2018-10-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Elanco Animal Health Inc Aktie (ELAN) Neueste Nachrichten
Elanco will detail first-quarter results in a May 6 webcast - Stock Titan
Elanco Animal Health Price Target Announced at $30.00/Share by Citigroup - Moomoo
Elanco Animal Health Inc (ELAN) Shares Fall 3.6% -- GF Value Says Still Overvalued - GuruFocus
ELAN Initiated Coverage by Citigroup -- Price Target Announced a - GuruFocus
Is Elanco (ELAN) Using Mass-Market Collars to Quietly Redefine Its Companion Animal Strategy? - Yahoo Finance
Is It Too Late To Consider Elanco Animal Health (ELAN) After Its 1-Year Share Price Surge? - Yahoo Finance
Animal Health Market Intelligence Report 2026-2034 Featuring Strategic Analysis of Bayer, Elanco, Merck, Merial, Zoetis, Boehringer Ingelheim, Ceva Sante Animale, Heska and More - Yahoo Finance
Citigroup Begins Coverage on Elanco Animal Health (NYSE:ELAN) - MarketBeat
Elanco Animal Health: Leading With Innovation, Impact, and Purpose - marketscreener.com
Elanco Animal Health Incorporated (NYSE:ELAN) Short Interest Up 49.0% in March - MarketBeat
630,840 Shares in Elanco Animal Health Incorporated $ELAN Acquired by Hardman Johnston Global Advisors LLC - MarketBeat
Elanco Animal Health Inc Investor Day Transcript - GuruFocus
Q3 2025 Elanco Animal Health Inc Earnings Call Transcript - GuruFocus
Institution Moves: Is Elanco Animal Health Incorporated gaining market shareEarnings Performance Report & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Where is Elanco Animal Health Incorporated (ELAN) headed according to the Street? - MSN
DDD Partners LLC Decreases Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
ELAN Stock Price, Quote & Chart | ELANCO ANIMAL HEALTH INC (NYSE:ELAN) - ChartMill
Elanco Animal Health Inc (STU:5EA) Bonds - GuruFocus
Elanco Animal Health Incorporat (ELAN) Stock forecasts - Yahoo Finance UK
Dimensional Fund Advisors (NYSE: ELAN) reports 24.5M shares beneficially owned - Stock Titan
Elanco Animal Health Inc (ELAN) Shares Gap Down to $22.82 on Apr 9 - GuruFocus
Elanco's new dog flea collar offers 4 months of coverage for under $25 - Stock Titan
Aug Sectors: Can Elanco Animal Health Incorporated expand its profit marginsLayoff News & Weekly Market Pulse Alerts - baoquankhu1.vn
Form DEF 14A Elanco Animal Health For: Dec 31 - StreetInsider
[DEF 14A] Elanco Animal Health Inc Definitive Proxy Statement - Stock Titan
BofA Securities Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Elanco (ELAN) executive awarded new deferred stock units under deferral plan - Stock Titan
Elanco (NYSE: ELAN) CEO awarded new deferred stock units as compensation - Stock Titan
Elanco (ELAN) CFO awarded new deferred stock units in Form 4 filing - Stock Titan
Elanco (ELAN) officer granted 40,985 shares, with 20,288 withheld for taxes - Stock Titan
Stifel reiterates buy on Elanco stock, keeps $32 price target - Investing.com
ELAN Technical Analysis | Trend, Signals & Chart Patterns | ELANCO ANIMAL HEALTH INC (NYSE:ELAN) - ChartMill
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
IVF In Animals Market Generated Opportunities, Future Scope - openPR.com
Veterinary Medication Market Set for Dynamic Boom as Key Players - openPR.com
Harbor Capital Advisors Inc. Sells 49,302 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
ELAN Technical Analysis & Stock Price Forecast - intellectia.ai
ELAN PE Ratio & Valuation, Is ELAN Overvalued - Intellectia AI
Maryland judge dismisses securities class action against Elanco over Zenrelia disclosures - DVM360
Elanco (ELAN) director defers fees into 600 Deferred Stock Units - Stock Titan
Elanco Animal Health Incorporated (ELAN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Assessing Elanco Animal Health’s Valuation After Recent Share Price Swings And Product Launch Momentum - Yahoo Finance
Chewy reaches settlement in Elanco flea and tick antitrust litigation - DVM360
Elanco supports incubaFORUM ASIA 2026 as Premium-Platinum Sponsor - avinews.com
Decoquinate Market Is Going to Boom Rapidly With Top Key Players - openPR.com
Companion Animal Health Market Forecast 2026-2033 Featuring Strategic Analysis of Agrolabo, Boehringer Ingelheim, Ceva, Elanco, IDEXX Labs and More - Yahoo Finance
Elanco Animal Health Inc (ELAN) Shares Gap Down to $23.21 on Mar 27 - GuruFocus
Elanco Beats Investor Suit Over Dog Drug's Reg Challenges - Law360
Elanco Animal Health Drops More Than 5% – What’s Behind the Abrupt Decline? - Bitget
Vanguard reports 0 shares of Elanco after realignment (NYSE: ELAN) - Stock Titan
Elanco Gets Investors’ Dog Itch Drug Development Suit Dismissed - news.bloomberglaw.com
Finanzdaten der Elanco Animal Health Inc-Aktie (ELAN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
2.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):